摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methanesulfonic acid 3a,4-dihydro-3H-2,5-dioxa-1,7-diaza-cyclopenta[a]naphthalen-3-ylmethyl ester | 666234-19-1

中文名称
——
中文别名
——
英文名称
methanesulfonic acid 3a,4-dihydro-3H-2,5-dioxa-1,7-diaza-cyclopenta[a]naphthalen-3-ylmethyl ester
英文别名
4,8-Dioxa-3,11-diazatricyclo[7.4.0.02,6]trideca-1(9),2,10,12-tetraen-5-ylmethyl methanesulfonate
methanesulfonic acid 3a,4-dihydro-3H-2,5-dioxa-1,7-diaza-cyclopenta[a]naphthalen-3-ylmethyl ester化学式
CAS
666234-19-1
化学式
C11H12N2O5S
mdl
——
分子量
284.293
InChiKey
SVIVCUXRUDUWCO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    95.5
  • 氢给体数:
    0
  • 氢受体数:
    7

文献信息

  • [EN] FUSED HETEROCYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS<br/>[FR] DERIVES D'ISOXAZOLINE HETEROCYCLIQUES FUSIONNES ET LEUR UTILISATION EN TANT QU'ANTIDEPRESSEURS
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2004018483A1
    公开(公告)日:2004-03-04
    The invention concerns fused heterocyclic isoxazoline derivatives of Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof, more in particular, tetrahydropyranoisoxazole, hexahydroisoxazolopyridine, tetrahydrothiopyrano isoxazole and hexahydrobenzoisoxazole derivatives fused to a heterocyclic ring system via the 6-membered ring of the bicyclic moiety as well as processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia, wherein the variables are defined as in Claim 1. The compounds have surprisingly been shown to have selective serotonine (5-HT) reuptake inhibitor activity as well as α2-adrenoceptor antagonist activity, compounds according to the invention are also suitable for treatment and/or prophylaxis in diseases where either one of the activities alone or the combination of said activities may be of therapeutic use.
    该发明涉及Formula (I)的融合杂环异氧化烷衍生物,其药学上可接受的酸或碱盐,其立体化异构体以及其N-氧化物形式,更具体地说,通过双环部分的6元环连接到杂环环系统的四氢吡喃异氧化烷,六氢异氧化烷吡啶,四氢喃异氧化烷和六氢苯并异氧化烷衍生物,以及它们的制备方法,包含它们的制药组合物以及它们作为药物的用途,特别是用于治疗抑郁症、焦虑症、运动障碍、精神病、帕森病和体重紊乱,包括厌食症和暴食症,其中变量的定义如权利要求书第1项所述。这些化合物被惊人地证明具有选择性的5-羟色胺(5-HT)再摄取抑制剂活性以及α2-肾上腺素受体拮抗剂活性,根据本发明的化合物也适用于治疗和/或预防在该活性之一或该活性的组合可能具有治疗用途的疾病。
  • Fused heterocyclic isoxazoline derivatives and their use as anti-derpressants
    申请人:Andres-Gil Ignacio Jose
    公开号:US20060116378A1
    公开(公告)日:2006-06-01
    The invention concerns fused heterocyclic isoxazoline derivatives of Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof, more in particular, tetrahydropyranoisoxazole, hexahydroisoxazolopyridine, tetrahydrothiopyrano isoxazole and hexahydrobenzoisoxazole derivatives fused to a heterocyclic ring system via the 6-membered ring of the bicyclic moiety as well as processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia, wherein the variables are defined as in Claim 1. The compounds have surprisingly been shown to have selective serotonine (5-HT) reuptake inhibitor activity as well as α 2 -adrenoceptor antagonist activity, compounds according to the invention are also suitable for treatment and/or prophylaxis in diseases where either one of the activities alone or the combination of said activities may be of therapeutic use.
    本发明涉及公式(I)的融合杂环异噁唑生物,其药学上可接受的酸或碱盐,其立体化异构体形式和N-氧化物形式,更具体地,通过双环基团的6元环与杂环环系统融合的四氢吡喃异噁唑,六氢异噁唑吡啶,四氢异噁唑和六氢苯并异噁唑生物,以及其制备方法,包括它们的制药组合物和作为药物的用途,特别是用于治疗抑郁症,焦虑症,运动障碍,精神病,帕森病和体重障碍,包括厌食症和贪食症,其中变量的定义如权利要求1所述。这些化合物已被证明具有选择性的5-羟色胺(5-HT)再摄取抑制剂活性以及α2-肾上腺素受体拮抗剂活性,根据本发明的化合物也适用于治疗和/或预防单独或联合使用这些活性可能具有治疗用途的疾病。
  • FUSED HETEROCYCLIC ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS
    申请人:JANSSEN PHARMACEUTICA N.V.
    公开号:EP1554286A1
    公开(公告)日:2005-07-20
  • US7501418B2
    申请人:——
    公开号:US7501418B2
    公开(公告)日:2009-03-10
查看更多